BridgeMD
L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma
EU CTIS ID: 2025-523231-19-00
What this study is testing
The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF in patients locally advanced cSCC progressed on or intolerant to systemic treatment.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients must have histologically documented, locally advanced cSCC. Patients must have at least one injectable and measurable cutaneous or subcutaneous lesion. Patients must have locally advanced cSCC that has progressed on or cannot tolerate ICI treatment (adjuvant or first line) as assessed by a local multidisciplinary tumor board. Patients with nodal, regional or in transit injectable cSCC lesions. Patients must be willing to provide tissue from a core or excisional biopsy of a tumor lesion at screening and for confirmation of Objective Response or Stable Disease.
- Male or female patients, age 18 - 100 years. ECOG Performance Status/WHO Performance Status ≤ 2. Hemoglobin > 10.0 g/dL. Platelets > 100 x 109/L. ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN). All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.
- Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening.
- Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception
- Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
You likely can't join if
- Presence of concomitant malignancies, with the exception of any cancer curatively treated more than 3 years prior to study entry and of tumors with a negligible risk for metastasis or death, such as adequately treated basal cell carcinoma of the skin (surgically removed at least 4 weeks prior to study entry), ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix, early-stage asymptomatic CLL and not under active treatment (Rai 0, Binet A) will be eligible for the study. • Radiation therapy on the tumor sites in the 4 weeks prior to study drug administration. • Current topical or systemic chemotherapy, immunotherapy. • Presence of visceral metastasis.
- Presence of active severe bacterial or viral infections or other severe concurrent disease/infection requiring therapy, including positive tests for human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV). For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
- History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris,inadequately treated cardiac arrhythmias and heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
- Any abnormalities observed during baseline ECG investigations that are considered clinically significant by the investigator.
- Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance < 45 mL/min/1.73m2
- Known arterial aneurysms.
See the full eligibility criteria
Who can join
- Patients must have histologically documented, locally advanced cSCC. Patients must have at least one injectable and measurable cutaneous or subcutaneous lesion. Patients must have locally advanced cSCC that has progressed on or cannot tolerate ICI treatment (adjuvant or first line) as assessed by a local multidisciplinary tumor board. Patients with nodal, regional or in transit injectable cSCC lesions. Patients must be willing to provide tissue from a core or excisional biopsy of a tumor lesion at screening and for confirmation of Objective Response or Stable Disease.
- Male or female patients, age 18 - 100 years. ECOG Performance Status/WHO Performance Status ≤ 2. Hemoglobin > 10.0 g/dL. Platelets > 100 x 109/L. ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN). All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.
- Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening.
- Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception
- Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
What rules you out
- Presence of concomitant malignancies, with the exception of any cancer curatively treated more than 3 years prior to study entry and of tumors with a negligible risk for metastasis or death, such as adequately treated basal cell carcinoma of the skin (surgically removed at least 4 weeks prior to study entry), ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix, early-stage asymptomatic CLL and not under active treatment (Rai 0, Binet A) will be eligible for the study. • Radiation therapy on the tumor sites in the 4 weeks prior to study drug administration. • Current topical or systemic chemotherapy, immunotherapy. • Presence of visceral metastasis.
- Presence of active severe bacterial or viral infections or other severe concurrent disease/infection requiring therapy, including positive tests for human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV). For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
- History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris,inadequately treated cardiac arrhythmias and heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
- Any abnormalities observed during baseline ECG investigations that are considered clinically significant by the investigator.
- Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance < 45 mL/min/1.73m2
- Known arterial aneurysms.
- INR > 3.
- Uncontrolled hypertension. • Known uncontrolled coagulopathy or bleeding disorder. • Known hepatic cirrhosis or severe pre-existing hepatic impairment. • Moderate to severe respiratory failure. • Active autoimmune disease that has required systemic treatment in past 2 years. • Patients have a diagnosis of immunodeficiency or are receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions and asthma/COPD is not considered an exclusion criterion.
- Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies. • Pregnancy or breast-feeding. • Ischemic peripheral vascular disease (Grade IIb-IV). • Severe diabetic retinopathy. • Recovery from major trauma including surgery within 4 weeks prior to enrollment. • Solid organ transplant recipient or patient with iatrogenic or pathologic severe immune suppression. • Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.